Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesArovella Therapeutics Ltd

Arovella Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.05 AUD 0.00(0%)
Last update at 2026-11-06T04:04:00Z
VOLUME
201328
Market Cap
60.44M

Momentum Score

…

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.05
Low
0.05
High
52 Week Price Range
0.05
Low
0.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Arovella Therapeutics Ltd is an Australian biotechnology company listed on the ASX that, based on limited public disclosures, develops therapeutic candidates. Its long-term growth drivers may include positive clinical and regulatory outcomes, licensing or partnering deals, and successful commercialization of lead programs, which could support scale and revenue expansion; investors may find potential upside from milestone-driven value creation.
The most important investment risks are high probability of clinical or regulatory failure, ongoing need for external funding that could dilute shareholders, competitive and intellectual property challenges, and limited public disclosure increasing information risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
-
Revenue TTM
3.50M
Revenue Per Share
0.00
Gross Profit TTM
3.50M
Debt / Equity
0.02
ROE
-40.41%
Net Debt
-14.35M
ROCE
-79.13%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -10.41M -7.51M -8.75M -11.23M -8.62M
Net income -6.92M -7.51M -8.75M -10.18M -8.62M
Selling general administrative 3.27M 3.06M 2.77M 3.10M 2.79M
Selling and marketing expenses - - 1.28M 0.43M -
Gross profit -0.12M 0.14M -0.03M -3.00M 0.09M
Reconciled depreciation 0.12M 0.11M 0.04M 0.84M 0.55M
Ebit -11.21M -11.20M -10.67M -9.68M -7.59M
Ebitda -11.10M -11.10M -10.63M -8.84M -7.04M
Depreciation and amortization 0.12M 0.11M 0.04M 0.84M 0.55M
Operating income -11.21M -11.20M -10.81M -9.68M -7.59M
Other operating expenses 11.21M 11.34M 10.83M 10.09M 7.89M
Interest expense - - 0.01M 0.02M 0.19M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.80M 0.39M 0.14M 0.02M 0.19M
Net interest income 0.80M 0.39M 0.13M 0.01M -0.19M
Income tax expense -3.50M -3.30M -1.94M -1.05M 0.19M
Total revenue - 0.14M 0.02M 0.41M 0.30M
Total operating expenses 11.10M 11.34M 10.79M 6.68M 7.69M
Cost of revenue 0.12M - 0.04M 3.41M 0.21M
Total other income expense net 0.80M 3.69M 2.07M -1.55M -0.83M
Net income from continuing ops -6.92M -7.51M -8.75M -10.18M -8.62M
Net income applicable to common shares - -7.51M -8.75M -10.18M -8.62M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 15.01M 21.60M 13.28M 5.47M 9.21M
Intangible assets - - - 0.00M 2.25M
Other current assets 0.30M 0.19M 0.44M 0.20M 0.48M
Total liab 0.86M 1.52M 2.06M 1.69M 1.60M
Total stockholder equity 14.15M 20.08M 11.23M 3.78M 7.62M
Deferred long term liab - - - - 2.12M
Other current liab 0.52M - 0.92M 0.61M 0.69M
Common stock 121.27M - 104.30M 88.87M 83.54M
Capital stock 121.27M 120.13M - 88.87M 83.54M
Retained earnings -108.62M -102.84M -95.51M -87.06M -77.02M
Other liab - - - 0.01M 0.01M
Other assets - - 0.00M - 2.12M
Cash 14.35M 20.88M 12.71M 5.18M 6.07M
Cash and equivalents - - - 5.18M 6.07M
Total current liabilities 0.84M 1.49M 2.04M 1.68M 1.51M
Current deferred revenue - - 0.14M - 0.35M
Net debt -14.35M - -12.71M - -5.93M
Short term debt - - - 0.00M 0.07M
Short long term debt - - - - 0.00M
Short long term debt total - - - - 0.14M
Other stockholder equity - - - 1.96M 1.11M
Property plant equipment - - - 0.05M 0.37M
Total current assets 14.66M 21.17M 13.15M 5.42M 6.59M
Net tangible assets - - - 3.78M 7.48M
Net receivables - - - 0.01M 0.04M
Accounts payable 0.32M 0.94M 0.98M 0.77M 0.75M
Accumulated other comprehensive income 1.50M - 2.44M - 1.11M
Non currrent assets other - - -0.00M - -
Non current assets total 0.35M 0.43M 0.13M 0.05M 2.62M
Capital lease obligations - - - - 0.14M
Long term debt total - - - 0.00M 0.08M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.43M -0.18M 0.10M -0.57M
Change to liabilities - - - 0.22M -0.27M
Total cashflows from investing activities -0.04M -0.43M -0.18M 0.10M -0.57M
Net borrowings - - - -0.07M -0.07M
Total cash from financing activities 0.49M 15.52M 14.61M 5.41M 6.19M
Change to operating activities - - - 0.26M -0.30M
Net income -6.92M -7.51M -8.75M -10.18M -8.62M
Change in cash -6.52M 8.16M 7.54M -0.90M -0.65M
Begin period cash flow 20.88M 12.71M 5.18M 6.07M 6.72M
End period cash flow 14.35M 20.88M 12.71M 5.18M 6.07M
Total cash from operating activities -6.91M -6.93M -6.91M -6.40M -6.27M
Issuance of capital stock 0.51M 16.81M 14.61M 5.48M 6.26M
Depreciation 0.12M - 0.04M 0.84M 0.55M
Other cashflows from investing activities -0.00M -0.02M -0.05M 0.10M -0.53M
Change to inventory - - - -0.00M -
Change to account receivables - - -0.01M 0.03M 0.50M
Sale purchase of stock -0.02M -1.29M 14.61M 5.48M 6.26M
Other cashflows from financing activities - - -0.18M -0.07M -0.07M
Change to netincome - - - 2.44M 1.87M
Capital expenditures 0.04M 0.41M 0.13M 0.00M 0.57M
Change in working capital -0.68M -0.38M 0.64M 0.51M -0.07M
Stock based compensation - - 1.05M 0.87M 0.58M
Other non cash items 0.57M -6.55M 0.10M 3.86M 2.75M
Free cash flow -6.95M -7.34M -7.04M -6.40M -6.83M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ALA
Arovella Therapeutics Ltd		 -
-%		 0.05 - - 17.28 4.27 726.66 -3.35
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Arovella Therapeutics Ltd

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

Corporate One, Preston, VIC, Australia, 3072

61 3 9863 6472

https://www.arovella.com

Name Title Year Born
Dr. Michael Baker CEO, MD & Director NA
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBA Company Sec. & CFO 1961
Mr. Stephen John Carter Consultant NA
Dr. Richard Franklin Project Director & Member of Scientific Advisory Board NA
Tony Macintyre GM & CTO NA
Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. Chief Operating Officer NA
Mr. Tim Luscombe B.Com., C.A. Company Secretary & CFO NA
Michelle Long Administration Manager NA
Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. Chief Operating Officer NA
Mr. Tim Luscombe B.Com., C.A. Company Secretary & CFO NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…